Literature DB >> 22116087

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Lucy S K Walker1, David M Sansom.   

Abstract

The T cell protein cytotoxic T lymphocyte antigen 4 (CTLA4) was identified as a crucial negative regulator of the immune system over 15 years ago, but its mechanisms of action are still under debate. It has long been suggested that CTLA4 transmits an inhibitory signal to the cells that express it. However, not all the available data fit with a cell-intrinsic function for CTLA4, and other studies have suggested that CTLA4 functions in a T cell-extrinsic manner. Here, we discuss the data for and against the T cell-intrinsic and -extrinsic functions of CTLA4.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116087     DOI: 10.1038/nri3108

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  155 in total

1.  Structural analysis of CTLA-4 function in vivo.

Authors:  E L Masteller; E Chuang; A C Mullen; S L Reiner; C B Thompson
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

2.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Authors:  Olivier Manches; David Munn; Anahita Fallahi; Jeffrey Lifson; Laurence Chaperot; Joel Plumas; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

5.  1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity.

Authors:  Sophie Agaugué; Laure Perrin-Cocon; Frédéric Coutant; Patrice André; Vincent Lotteau
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

6.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

Authors:  E A Tivol; S D Boyd; S McKeon; F Borriello; P Nickerson; T B Strom; A H Sharpe
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

7.  Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases.

Authors:  E Chuang; K M Lee; M D Robbins; J M Duerr; M L Alegre; J E Hambor; M J Neveu; J A Bluestone; C B Thompson
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

8.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

9.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms.

Authors:  Wataru Ise; Masako Kohyama; Katherine M Nutsch; Hyang Mi Lee; Anish Suri; Emil R Unanue; Theresa L Murphy; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2009-12-27       Impact factor: 25.606

View more
  254 in total

Review 1.  Genomics of Immune Diseases and New Therapies.

Authors:  Michael Lenardo; Bernice Lo; Carrie L Lucas
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

2.  ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation.

Authors:  Nicholas A Zumwalde; Eisuke Domae; Matthew F Mescher; Yoji Shimizu
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

3.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Authors:  Hyun-Bae Jie; Patrick J Schuler; Steve C Lee; Raghvendra M Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L Whiteside; Robert L Ferris
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

4.  Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Authors:  A Picchianti Diamanti; M M Rosado; M Scarsella; V Germano; E Giorda; S Cascioli; B Laganà; R D'Amelio; R Carsetti
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

5.  Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

Authors:  Charlotte Schwab; Annemarie Gabrysch; Peter Olbrich; Virginia Patiño; Klaus Warnatz; Daniel Wolff; Akihiro Hoshino; Masao Kobayashi; Kohsuke Imai; Masatoshi Takagi; Ingunn Dybedal; Jamanda A Haddock; David M Sansom; Jose M Lucena; Maximilian Seidl; Annette Schmitt-Graeff; Veronika Reiser; Florian Emmerich; Natalie Frede; Alla Bulashevska; Ulrich Salzer; Desirée Schubert; Seiichi Hayakawa; Satoshi Okada; Maria Kanariou; Zeynep Yesim Kucuk; Hugo Chapdelaine; Lenka Petruzelkova; Zdenek Sumnik; Anna Sediva; Mary Slatter; Peter D Arkwright; Andrew Cant; Hanns-Martin Lorenz; Thomas Giese; Vassilios Lougaris; Alessandro Plebani; Christina Price; Kathleen E Sullivan; Michel Moutschen; Jiri Litzman; Tomas Freiberger; Frank L van de Veerdonk; Mike Recher; Michael H Albert; Fabian Hauck; Suranjith Seneviratne; Jana Pachlopnik Schmid; Antonios Kolios; Gary Unglik; Christian Klemann; Carsten Speckmann; Stephan Ehl; Alan Leichtner; Richard Blumberg; Andre Franke; Scott Snapper; Sebastian Zeissig; Charlotte Cunningham-Rundles; Lisa Giulino-Roth; Olivier Elemento; Gregor Dückers; Tim Niehues; Eva Fronkova; Veronika Kanderová; Craig D Platt; Janet Chou; Talal A Chatila; Raif Geha; Elizabeth McDermott; Su Bunn; Monika Kurzai; Ansgar Schulz; Laia Alsina; Ferran Casals; Angela Deyà-Martinez; Sophie Hambleton; Hirokazu Kanegane; Kjetil Taskén; Olaf Neth; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2018-05-04       Impact factor: 10.793

6.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 7.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

8.  Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.

Authors:  Shabnam Abtahi; Fatemeh Izadi Jahromi; Mohammad Hossein Dabbaghmanesh; Mahyar Malekzadeh; Abbas Ghaderi
Journal:  Endocrine       Date:  2018-08-04       Impact factor: 3.633

9.  High viral burden restricts short-lived effector cell number at late times postinfection through increased natural regulatory T cell expansion.

Authors:  Samuel Amoah; Beth C Holbrook; Rama D Yammani; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 10.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.